Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging
Dongjun Li,Michael Kirberger,Jingjuan Qiao,Zongxiang Gui,Shenghui Xue,Fan Pu,Jie Jiang,Yiting Xu,Shanshan Tan,Mani Salarian,Oluwatosin Ibhagui,Khan Hekmatyar,Jenny J. Yang
DOI: https://doi.org/10.1097/rli.0000000000001057
IF: 6.7
2024-01-06
Investigative Radiology
Abstract:Chronic diseases including alcoholic steatohepatitis (ASH), nonalcoholic steatohepatitis (NASH), and various types of cancers are results of perturbations of common molecular determinants in key biological and signaling processes. Noninvasive imaging is critical for characterizing dynamic changes of molecular disease biomarkers for disease progression and regression upon treatment or during therapy. Compared with x-rays and computed tomography, magnetic resonance imaging (MRI) provides improved imaging sensitivity of soft tissues, including nerves, muscles, ligaments, and tendons, without using ionizing radiation. Magnetic resonance imaging also provides better resolution, more comprehensive functional information, and better organ differentiation than ultrasound. In addition, it allows us to capture dynamic signal changes. Magnetic resonance imaging has emerged to be a primary imaging modality for both clinical and preclinical applications including but not limited to cardiac imaging for heart diseases; 1 neuroimaging for Parkinson disease 2 and epilepsy 3 ; and cancer imaging for primary and metastatic cancers, 4 including brain tumors 5 and hepatocellular carcinoma (HCC). 6 This wide array of applications is largely due to the discovery and development of MRI contrast agents (CAs). 7
radiology, nuclear medicine & medical imaging